GLYC

Uproleselan/GMI-1687

Relapsed/Refractory AML

Phase 3

Exp Date

2H 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Uproleselan/GMI-1687 for Relapsed/Refractory AML   - Phase 3

  • ClinicalTrial.gov (NCT03616470): Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia


WHAT IS THE NEXT CATALYST EVENT?

  • Completion of Enrollment 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 2H 2021 


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin. 

Updated by JM 

GLYC, Glycomimetics, Uproleselan/GMI-1687, Relapsed/Refractory AML


Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon